In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Quantitative assessment of LV volumes and function before chemotherapy: how to optimize and improve image quality of contrast echo examinations

EACVI webinar

18/10/2018 18:00 18/10/2018 19:00 Europe/Paris Quantitative assessment of LV volumes and function before chemotherapy: how to optimize and improve image quality of contrast echo examinations

Access event page

European Association of Cardiovascular Imaging DD/MM/YYYY
Contrast Echocardiography
Cardiovascular Disease in Special Populations

Focus on

Learning objectives: 

  • to understand the importance of accurate and reproducible LV volume measurements for the assessment of cardiac toxicity of cancer therapies
  • to implement echocardiography in the therapy management of cancer patients
  • to understand the impact of machine settings on the image quality of contrast echo examinations
  • to optimise diagnostic accuracy and confidence of contrast echocardiography

Watch the webinar recording


Andreas Helfen answers your question

Does the assessment of diastolic Function play any role in this scenario?

Answer from Dr Helfen:

The 2016 ESC position paper on cancer treatments (EHJ (2016) 37,2768-2801) lists “heart failure with preserved ejection fraction”, another term for “diastolic dysfunction with normal ejection fraction” as a baseline risk factor for cardiotoxicity. Therefore, these patients need a careful follow-up. In the case of manifestation of cardiotoxicity with a decrease of more than 10% percentage points below the lower limit of normal diastolic dysfunction is always present. In this situation we start the therapy recommended for patients with heart failure due to cardiomyopathy. Therefore, assessment of diastolic function plays a role.



2018_Harald_Becher.jpgDoctor Harald H Becher
Mazankowski Alberta Heart Institute
Alberta, Canada


Helfen_Andreas_2016.jpgDoctor Andreas Helfen
St Marien Hospital Medizinische Klinik I
LÜnen, Germany


2018_Piotr_Lipiec.jpgProfessor Piotr Lipiec
Department of Cardiology
Medical University of Lodz, Poland


Session information

The webinar addresses cardiologists working in the field of multimodality imaging (Echo, CMR, Nuclear) and cardiovascular imaging community.

During the webinar, you will be encouraged to send your questions by chat and interact with our key opinion leaders who will provide live feedback.

Technical settings

The webinar is available on PC and Tablets. The use of a smartphone is not recommended.

To answer the MCQs during the live, you must allow pop-up windows.

A high-speed Internet connection is required (minimum 2 Mbps).